

RESEARCH

BOB Economics Research | RBI FSR

Emerging stress in MSMEs and Consumer loans

BOB Economics Research | Trade

Exports see a stellar recovery

SUMMARY

India Economics: RBI FSR

While RBI has lowered its banking sector stress projections, it has pointed out rising stress in MSME loans of PSBs and consumer credit in case of PVBs and NBFCs. Economy is showing signs of recovery which may lead to lower stress build up. However, FSR alludes to new risks emerging from another wave, rising international commodity prices and inflationary pressures therein. We expect GDP growth at 9.7% in FY22 and RBI to normalize monetary policy in Q4FY22 by raising reverse repo rate.

[Click here for the full report.](#)

India Economics: Trade

India's trade deficit rose to US\$ 9.4bn from US\$ 6.3bn in May'21 led by higher oil and non-oil-non-gold imports. Over a 2-year period, exports have risen by 29.7%. On the other hand, imports have increased by only 2%, led by lower gold imports. Non-oil-non-gold imports, barometer of demand, have increased by 11.3%. We expect non-oil imports to improve as domestic restrictions are eased. Exports are likely to remain buoyant implying a trade deficit of US\$ 165bn in FY22 (US\$ 102.2bn in FY21).

[Click here for the full report.](#)

Daily macro indicators

Indicator	Current	2D (%)	1M (%)	12M (%)
US 10Y yield (%)	1.46	(1bps)	(14 bps)	79 bps
India 10Y yield (%)	6.04	(1 bps)	2 bps	20 bps
USD/INR	74.56	(0.3)	(2.7)	0.6
Brent Crude (US\$/bbl)	75.84	0.9	9.4	75.8
Dow	34,634	0.4	0.3	34.1
Shanghai	3,589	(0.1)	(0.7)	16.1
Sensex	52,319	(0.3)	0.7	46.0
India FII (US\$ mn)	30-Jun	MTD	CYTD	FYTD
FII-D	(3.1)	(586.2)	(3,166.8)	(1,139.5)
FII-E	(150.7)	1,498.1	8,084.2	757.8

Source: Bank of Baroda Economics Research



RBI FINANCIAL STABILITY REPORT (FSR)

02 July 2021

Emerging stress in MSMEs and Consumer loans

While RBI has lowered its banking sector stress projections, it has pointed out rising stress in MSME loans of PSBs and consumer credit in case of PVBs and NBFCs. Economy is showing signs of recovery which may lead to lower stress build up. However, FSR alludes to new risks emerging from another wave, rising international commodity prices and inflationary pressures therein. We expect GDP growth at 9.7% in FY22 and RBI to normalize monetary policy in Q4FY22 by raising reverse repo rate.

Sameer Narang |
Dipanwita Mazumdar | Jahnavi
chief.economist@bankofbaroda.com

Signs of recovery: RBI exudes optimism on recovery in FSR with COVID-19 infections falling in India and pace of vaccinations picking up. Global financial markets are upbeat on reflation trade. Indian equity markets are increasingly confident of a recovery. However, FSR alludes to emerging risks in the form of future waves of the pandemic, international commodity prices and inflationary pressures, global spillovers amid high uncertainty, and rising incidence of data breaches and cyber-attacks. Accordingly, sustained policy support remains vital.

Lower stress projections...: RBI clearly states that the dent on balance sheets and performance of financial institutions in India has been much less than what was projected earlier, although a clearer picture will emerge as the effects of regulatory relief fully work their way through. GNPA ratio of SCBs is expected to increase to 9.8% in Mar'22 (base case) from 7.48% in Mar'21. In the previous issue of FSR, RBI had projected GNPA ratio to increase to 13.5% in Sep'21 (7.5% in Sep'20). Now even under severe stress, GNPA ratio can increase only to 11.22% in Mar'22. Even capital position is expected to be better with CRAR of SCBs at 15.54% in Mar'22 (base case) from 15.84% in Mar'21. It was projected at 14% in Sep'21 earlier.

...however, stress is building up: Despite restructuring, stress in MSME portfolio of PSBs has inched up. Outstanding loans in SMA0 bucket are at 10.6% (7.8% in Dec'20), SMA1 are at 9.2% (5.6% in Dec'20) and NPA ratio has increased to 15.9% (13.1% in Dec'20). Even in consumer credit, delinquency ratios have seen a large increase for PVBs at 2.4% in Jan'21 (1.2% in Jan'20) and NBFC/HFCs at 6.7% in Jan'21 (5.3% in Jan'20). In wholesale credit, out of Rs 23.09tn outstanding in Sep'20, 7% is now in SMA0 and 2.8% is in SMA1 in Apr'21.

Economy to rebound: Economic impact of second wave is less severe than first wave. Our economy tracker is 8% below Feb'20 baseline compared with 19% dip in May'21. Recent high frequency indicators show a steady turnaround. We expect GDP growth at 9.7% in FY22 led by recovery in industrial activity and normalization of services (post vaccination). RBI is likely to look at normalizing monetary policy in Q4FY22 by reducing gap between repo and reverse repo rates.

Key highlights

- Stress test shows GNPA ratio to rise to 9.8% in Mar'22, under baseline scenario.
- Emerging stress in MSME portfolio of PSBs.
- Consumer credit stress rising for PVBs and NBFC/ HFCs.
- Macroeconomic risks in the form of another wave, rising commodity prices and inflation.



TRADE

02 July 2021

Exports see a stellar recovery

India's trade deficit rose to US\$ 9.4bn from US\$ 6.3bn in May'21 led by higher oil and non-oil-non-gold imports. Over a 2-year period, exports have risen by 29.7%. On the other hand, imports have increased by only 2%, led by lower gold imports. Non-oil-non-gold imports, barometer of demand, have increased by 11.3%. We expect non-oil imports to improve as domestic restrictions are eased. Exports are likely to remain buoyant implying a trade deficit of US\$ 165bn in FY22 (US\$ 102.2bn in FY21).

Sameer Narang | Aditi Gupta
 Sonal Badhan

chief.economist@bankofbaroda.com

Export growth steady: As per preliminary data, India's exports were stable at US\$ 32.5bn in Jun'21 compared with US\$ 32.3bn in May'21. However, on a low base exports have increased by 47.3% in Jun'21 on a YoY basis. Notably, exports had fallen by 12% in Jun'20. Oil exports have increased at a much faster pace at 105.2%. Non-oil exports are up by 41.8%. Within non-oil exports, engineering goods (52.6%) and gems and jewellery (80.5%) have risen the most. Notably, over a 2-year horizon (since Jun'19) exports have picked up sharply by 29.7% in Jun'21 compared with an 8.1% increase in May'21. Over the same time period, non-oil exports are up by 27.3% and oil exports have risen by 49.8%. Within non-oil exports, chemicals (62.4%), and engineering goods (41.7%) have risen the most. On the other hand, exports of gems and jewellery have fallen by 10.8%. Export growth is expected to remain resilient due to improvement in external demand.

Imports rise: India's imports rose to US\$ 41.9bn in Jun'21 from US\$ 38.6bn in May'21. On a YoY basis, the increase is quite steep at 96.3%. A low base explains this as imports fell by 48% in Jun'20. While oil imports have increased by 114.9% over the last year, non-oil-non-gold imports have risen by 91.9% to US\$ 30.2bn in Jun'21. Within this, imports of pearls and precious stones (305%) and electronics (45.3%) have increased the most. On the other hand, imports of silver (91.4%) and project goods (12.5%) declined in Jun'21. Over a 2-year horizon, imports have increased by only 2%, led by decline in gold (64%) and oil (4.7%) imports. Non-oil-non-gold imports have remained resilient and increased by 11.3%.

Trade deficit widens: India's trade deficit expanded to US\$ 9.4bn in Jun'21 from US\$ 6.3bn in May'21 led by higher oil and non-oil-non-gold imports. The pickup in non-oil-non-gold imports is likely to gain further momentum as domestic activity picks up. Oil imports are also likely to be higher due to rising oil prices. Exports have remained resilient so far and will see a pickup as global demand improves further. As a result, we expect trade deficit to widen to US\$ 165bn in FY22 from US\$ 102.2bn in FY21, assuming oil prices sustain at current levels (US\$ 75/bbl). Even so, CAD is likely to remain within 1.5% of GDP. Thus, we expect INR to trade in range of 73-75/\$. Higher oil prices and another Covid wave are a risk to our view.

Key highlights

- Exports steady at US\$ 32.5bn (47.3% YoY) in Jun'21 versus US\$ 32.3bn (69.4%) in May'21.
- Imports rose to US\$ 41.9bn (96.3% YoY) in Jun'21 versus US\$ 38.6bn in May'21.
- Oil imports rise further to US\$ 10.7bn in Jun'21
- Trade deficit expanded to US\$ 9.4bn in Jun'21 from US\$ 6.3bn in May'21.



Disclaimer

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Rating distribution

As of 30 June 2021, out of 95 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 44 have BUY ratings, 7 have HOLD ratings, 17 are rated ADD*, 4 are rated REDUCE* and 23 are rated SELL. None of these companies have been investment banking clients in the last 12 months. (*Our ADD and REDUCE ratings are in the process of being migrated to the new recommendation structure.)

Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed

in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.